Explore

TrendlineTrendline
Beyond and Daring Innovate Plant Protein Market with New Product Lines

Beyond and Daring Innovate Plant Protein Market with New Product Lines

Beyond and Daring Innovate Plant Protein Market with New Product Lines
TrendlineTrendline
Seventh Circuit Court Revives Nationwide 'Zero Sugar' Class Action, Rules Allulose is a Sugar Under FDA Regulations

Seventh Circuit Court Revives Nationwide 'Zero Sugar' Class Action, Rules Allulose is a Sugar Under FDA Regulations

Seventh Circuit Court Revives Nationwide 'Zero Sugar' Class Action, Rules Allulose is a Sugar Under FDA Regulations
Rapid ReadRapid Read
FDA Emphasizes Broad-Spectrum SPF 15+ Sunscreen for Skin Cancer and Aging Prevention

FDA Emphasizes Broad-Spectrum SPF 15+ Sunscreen for Skin Cancer and Aging Prevention

The U.S. Food and Drug Administration (FDA) continues to evaluate sunscreen products to ensure their safety and effectiveness. A key focus of their guidance is the distinction between sunscreens that merely prevent sunburn and those that offer broader protection against skin cancer and early skin aging. According to US labeling law, only broad-spectrum sunscreens with a Sun Protection Factor (SPF) of 15 or higher can claim to reduce the risk of skin cancer and premature skin aging. Products with lower SPF values or those not classified as broad-spectrum must carry a warning indicating they only help prevent sunburn. The FDA recommends using broad-spectrum sunscreens with an SPF of at least 15 year-round, even on cloudy days, to protect against both UVA and UVB rays. These rays are responsible for sun damage, sunburn, and contribute to skin cancer and aging. The agency also specifies that only sunscreens in lotion, cream, stick, gel, oil, butter, paste, ointment, spray, and powder forms can be legally marke...
The Columbus DispatchThe Columbus Dispatch
In Ohio, new cases of illness caused by cyclospora parasite down again

In Ohio, new cases of illness caused by cyclospora parasite down again

New cases of cyclosporiasis, which causes explosive diarrhea, dropped 75% from the previous week according the Ohio Department of Health.
Rapid ReadRapid Read
FDA Approves Simtriyo, a New ADHD Medication for Adults and Children Aged 6 and Older

FDA Approves Simtriyo, a New ADHD Medication for Adults and Children Aged 6 and Older

The U.S. Food and Drug Administration (FDA) has approved Simtriyo (centanafadine), a new once-daily extended-release capsule for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children aged 6 and older. Simtriyo is classified as a central nervous system stimulant but operates differently from traditional ADHD stimulants by acting on three neurotransmitters: dopamine, norepinephrine, and serotonin. Traditional stimulants primarily target dopamine and norepinephrine, while serotonin is involved in mood and emotional processing. Clinical trials demonstrated that Simtriyo improved core ADHD symptoms, though it has not been directly compared to other ADHD medications. The drug's manufacturer, Otsuka, suggests Simtriyo may help with emotional dysregulation and executive function, benefits that were observed in exploratory post hoc analyses of trial data. Simtriyo is not yet commercially available as it awaits controlled substance scheduling by the U.S. Drug Enforcement Administrat...
Rapid ReadRapid Read
Online Platform Made-in-China Agrees to Halt Sales of Unapproved GLP-1 Drugs to U.S. Customers

Online Platform Made-in-China Agrees to Halt Sales of Unapproved GLP-1 Drugs to U.S. Customers

The international online platform Made-in-China has reached a settlement with the Connecticut Attorney General's office, agreeing to cease the sale of unapproved GLP-1 weight-loss medications to customers in the United States. The platform was found to be selling 'research grade' GLP-1 drugs without prescriptions or medical oversight, which are not approved for human use by the U.S. Food and Drug Administration (FDA). These drugs were often falsely marketed as generic versions of popular brand-name medications like Ozempic and Wegovy, but were found to contain impurities, potential bacterial contamination, and inconsistent active ingredient quantities, posing significant health risks. Made-in-China will implement a monitoring system to remove GLP-1 drug listings within five days and faces a $300,000 penalty, with $30,000 payable immediately and the remainder suspended pending compliance.
TrendlineTrendline
Aleph Farms Secures Singapore Approval for Cultivated Beef Steak, Eyes 2027 Launch

Aleph Farms Secures Singapore Approval for Cultivated Beef Steak, Eyes 2027 Launch

Aleph Farms Secures Singapore Approval for Cultivated Beef Steak, Eyes 2027 Launch
TrendlineTrendline
U.S. Egg Industry Faces Challenges in Adopting In-Ovo Sexing Technology Despite European Progress

U.S. Egg Industry Faces Challenges in Adopting In-Ovo Sexing Technology Despite European Progress

U.S. Egg Industry Faces Challenges in Adopting In-Ovo Sexing Technology Despite European Progress
Rapid ReadRapid Read
Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Prepares for First Human Trial of CRISPR Cholesterol Therapy EDIT-401

Editas Medicine is advancing towards a first-in-human study for EDIT-401, an in vivo CRISPR-edited medicine designed to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. According to CEO Gilmore O’Neill, the company is focused on in vivo CRISPR-edited medicines that offer differentiated efficacy and utilize gene-editing capabilities. EDIT-401 aims to increase the production of LDL receptors in liver cells, thereby enhancing the removal of LDL cholesterol from the bloodstream. Preclinical findings in non-human primates showed a mean reduction of 90% in LDL cholesterol, lipoprotein(a), and apolipoprotein B. The treatment is designed as a single intravenous infusion. Editas Medicine has submitted documentation to human research ethics committees in Australia and plans to dose the first patients this year. The Phase 1 trial will involve serial dose-escalation cohorts and an expansion into a broader patient population. The company anticipates sharing safety data in the first qu...
Rapid ReadRapid Read
Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics plc, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel). This designation is specifically for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The RMAT designation is a program established under the 21st Century Cures Act, designed to expedite the development and regulatory review process for regenerative medicine therapies, including cell therapies, that are intended to treat serious or life-threatening diseases. Autolus Therapeutics is currently enrolling patients in LUMINA, a pivotal Phase 2 study for obe-cel in refractory lupus nephritis, and expects to report data in 2028. The company also submitted a data update from the Phase 1 CARLYSLE trial for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.
Rapid ReadRapid Read
ARPA-H Initiates Program to Develop FDA-Authorized Clinical AI for Cardiovascular Care

ARPA-H Initiates Program to Develop FDA-Authorized Clinical AI for Cardiovascular Care

The Advanced Research Projects Agency for Health (ARPA-H) has launched the Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program, committing up to $33.7 million in its first year. This four-year program, with a total budget of $62.7 million, aims to create the world's first reliable, FDA-authorized clinical agentic AI system for 24/7 cardiovascular care. The goal is to establish a digital member of the clinical care team that can autonomously support heart failure patients between visits and escalate to human care teams when necessary. Selected teams, including Atman Health, Tempus AI, and Updoc, will develop patient-facing clinical AI agents. Stanford University will develop a supervisory AI agent to monitor these clinical agents for safety and out-of-distribution behavior. Duke University and Kaiser Permanente will focus on scalable implementation strategies within health systems, particularly in rural and underserved communities. The program will engage the U.S. Food and Drug Administ...
Rapid ReadRapid Read
Q'Apel Medical Launches Lynx Aspiration Catheter System in U.S. for Stroke Intervention

Q'Apel Medical Launches Lynx Aspiration Catheter System in U.S. for Stroke Intervention

Q'Apel Medical, a company specializing in neurovascular intervention, has announced the U.S. launch of its Lynx Aspiration Catheter System. This new system is designed to assist physicians performing mechanical thrombectomy, a critical procedure for treating acute ischemic stroke caused by vessel occlusion. The Lynx system aims to provide enhanced performance for clot retrieval and navigation through complex cerebrovascular anatomy. It features a bimetal shaft design for balanced support and flexibility, along with an open-spaced nitinol structure for kink resistance and structural resilience. The system is built on Q'Apel's proprietary QLCT™ (Q'Apel Laser Cut Tube) technology and offers three different internal diameter sizes (0.044-inch, 0.058-inch, and 0.072-inch) to optimize vessel-to-catheter ratios and ensure coaxial compatibility. This launch expands Q'Apel's neurovascular portfolio, offering a versatile toolset for stroke intervention following its U.S. Food and Drug Administration (FDA) clearance.